Skip to main content

Advertisement

SpringerLink
Log in

Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

BRCAness breast tumors represent a group of sporadic tumors characterized by a reduction in BRCA1 gene expression. As BRCA1 is involved in double-strand breaks (DSBs) repair, dysfunctional BRCA pathway could make a tumor sensitive to DNA damaging drugs (e.g., platinum agents). Thus, accurately identifying BRCAness could contribute to therapeutic decision making in patients harboring these tumors. The purpose of this study was to identify if BRCAness tumors present a characteristic methylation profile and/or were related to specific clinico-pathological features. BRCAness was measured by MLPA in 63 breast tumors; methylation status of 98 CpG sites within 84 cancer-related genes was analyzed by MS-MLPA. Protein and mRNA expressions of the selected genes were measured by quantitative real-time PCR and Western Blot. BRCAness was associated with younger age, higher nuclear pleomorfism, and triple-negative (TN) status. Epigenetically, we found that the strongest predictors for BRCAness tumors were the methylations of MLH1 and PAX5 plus the unmethylations of CCND2 and ID4. We determined that ID4 unmethylation correlated with the expression levels of both its mRNA and protein. We observed an inverse relation between the expressions of ID4 and BRCA1. To the best of our knowledge, this is the first report suggesting an epigenetic regulation of ID4 in BRCAness tumors. Our findings give new information of BRCAness etiology and encourage future studies on potential drug targets for BRCAness breast tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Larsen MJ, Thomassen M, Gerdes AM, Kruse TA (2014) Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl.) 8:145–155

    CAS  PubMed Central  Google Scholar 

  2. Domchek SM (2015) Evolution of genetic testing for inherited susceptibility to breast cancer. J Clin Oncol 33:295–296

    Article  PubMed  CAS  Google Scholar 

  3. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819

    Article  PubMed  CAS  Google Scholar 

  4. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Bruggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391–400

    Article  PubMed  CAS  Google Scholar 

  5. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11:4003–4011

    Article  PubMed  CAS  Google Scholar 

  6. Apostolou P, Fostira F (2013) Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013:747318

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chalasani P, Livingston R (2013) Differential chemotherapeutic sensitivity for breast tumors with “BRCAness”: a review. Oncologist 18:909–916

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7:60

    PubMed  PubMed Central  Google Scholar 

  9. Carey JP, Knowell AE, Chinaranagari S, Chaudhary J (2013) Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells. Anticancer Res 33:4271–4278

    PubMed  CAS  PubMed Central  Google Scholar 

  10. Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del BD, Strano S, Blandino G (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16:1086–1093

    Article  PubMed  CAS  Google Scholar 

  11. Galatro TF, Uno M, Oba-Shinjo SM, Almeida AN, Teixeira MJ, Rosemberg S, Marie SK (2013) Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels. PLoS ONE 8:e61605

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DS (2005) Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24:4721–4727

    Article  PubMed  CAS  Google Scholar 

  13. Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA 98:130–135

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Branham MT, Marzese DM, Laurito SR, Gago FE, Orozco JI, Tello OM, Vargas-Roig LM, Roque M (2012) Methylation profile of triple-negative breast carcinomas. Oncogenesis 1:e17

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Marzese DM, Gago FE, Vargas-Roig LM, Roque M (2010) Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 24:271–280

    Article  PubMed  CAS  Google Scholar 

  16. Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, Imholz AL, Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S (2011) Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 13:R107

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Joosse SA, Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM (2009) Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 116:479–489

    Article  PubMed  CAS  Google Scholar 

  18. Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH (2012) Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol 23:2301–2305

    Article  PubMed  CAS  Google Scholar 

  19. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33:e128

    Article  PubMed  PubMed Central  Google Scholar 

  20. Marzese DM, Gago FE, Vargas-Roig LM, Roque M (2010) Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 24:271–280

    Article  PubMed  CAS  Google Scholar 

  21. Urrutia G, Laurito S, Marzese DM, Gago F, Orozco J, Tello O, Branham T, Campoy EM, Roque M (2015) Epigenetic variations in breast cancer progression to lymph node metastasis. Clin Exp Metastasis 32:99–110

    Article  PubMed  CAS  Google Scholar 

  22. Lips EH, Mulder L, Oonk A, Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM (2013) Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 108:2172–2177

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Dell’Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G (2010) ID4: a new player in the cancer arena. Oncotarget 1:48–58

    Article  PubMed  PubMed Central  Google Scholar 

  24. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R, Dahl E (2008) Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8:154

    Article  PubMed  PubMed Central  Google Scholar 

  25. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De NA, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126–2132

    Article  PubMed  CAS  Google Scholar 

  27. Suh DH, Kim MK, Kim HS, Chung HH, Song YS (2013) Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. J. Cancer Prev 18:227–234

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lee JY, Jeong W, Kim JH, Kim J, Bazer FW, Han JY, Song G (2012) Distinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomas. PLoS ONE 7:e51592

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Moelans CB, Verschuur-Maes AH, van Diest PJ (2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 225:222–231

    Article  PubMed  CAS  Google Scholar 

  30. Crippa E, Lusa L, De CL, Marchesi E, Calin GA, Radice P, Manoukian S, Peissel B, Daidone MG, Gariboldi M, Pierotti MA (2014) miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS ONE 9:e87039

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chatagnon A, Perriaud L, Nazaret N, Croze S, Benhattar J, Lachuer J, Dante R (2011) Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions. Epigenetics 6:1295–1307

    Article  PubMed  CAS  Google Scholar 

  32. Martini M, Cenci T, D’Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De MR, Pallini R, Larocca LM (2013) Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer 119:1004–1012

    Article  PubMed  CAS  Google Scholar 

  33. Roldan G, Delgado L, Muse IM (2006) Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer Biol Ther 5:505–510

    Article  PubMed  CAS  Google Scholar 

  34. de Candia P, Benera R, Solit DB (2004) A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res 92:81–94

    Article  PubMed  Google Scholar 

  35. Perk J, Iavarone A, Benezra R (2005) Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5:603–614

    Article  PubMed  CAS  Google Scholar 

  36. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC (2002) BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 99:7560–7565

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Reinbolt RE, Hays JL (2013) The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 3:237

    Article  PubMed  PubMed Central  Google Scholar 

  38. Branham RL Jr (1990) Scientific data analysis. Springer, New York

    Book  Google Scholar 

  39. Van Huffel S, Wandewalle J (1991) The total least squares problem: computational aspects and analysis. SIAM, Philadelphia

    Book  Google Scholar 

  40. Branham RL Jr (2001) Astronomical data reduction with total least squares. New Astron Rev 45:649–661

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported in part by the National Institute of Cancer (“Instituto Nacional del Cancer”), Argentina. RU was supported by funding from the National Institutes of Health (grant DK52913), the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701), and the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567 to GL).

Author information

Authors and Affiliations

  1. IHEM-CCT-CONICET Mendoza and National University of Cuyo, Mendoza, Argentina

    M. T. Branham, E. Campoy, S. Laurito, G. Urrutia & M. Roqué

  2. IANIGLA-CCT-CONICET Mendoza, Mendoza, Argentina

    R. Branham

  3. Gineco-Mamario Institute of Mendoza, Mendoza, Argentina

    J. Orozco & F. Gago

  4. GI Research Unit, Division of Gastroenterology and Hepatology, Epigenomics Translational Program, Center for Individualized Medicine, Mayo Clinic, Rochester, USA

    R. Urrutia

Authors
  1. M. T. Branham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Campoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Laurito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Branham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Urrutia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Orozco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Gago
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Urrutia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Roqué
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. T. Branham.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and animal rights

This article does not contain any studies with animals performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 69 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Branham, M.T., Campoy, E., Laurito, S. et al. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer. Breast Cancer Res Treat 155, 13–23 (2016). https://doi.org/10.1007/s10549-015-3648-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3648-0

Keywords

Search

Navigation